{
  "outcomes_metadata": {
    "timestamp": "2025-10-04T14:45:10.185761",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 120,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "mortality",
        "long-term survival",
        "perioperative mortality",
        "treatment-related mortality",
        "death",
        "survival",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression",
        "time to radiological disease progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to progression of the tumor",
        "time-to-progression",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "time to deterioration",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "disease recurrence",
        "recurrence",
        "early detection of local recurrence",
        "early detection of de novo tumor",
        "death state (partitioned survival model)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "tumor response rate",
        "tumour response (mRECIST)",
        "tumour response (RECIST criteria)",
        "tumour response (multiphase computed tomography with contrast)",
        "tumour response (magnetic resonance imaging with contrast)",
        "tumour response (measured by multiphasic CT, MRI, CT and MRI Liver Imaging Reporting and Data System (LI-RADS) v2018, contrast-enhanced ultrasound)",
        "tumour response",
        "objective tumour response",
        "response rates (RECIST criteria)",
        "response rate",
        "partial response (PR)",
        "partial response",
        "minor response (reduction of tumour size by 25 to 50%)",
        "complete response (CR)",
        "complete remission",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "clinical benefit rate",
        "success rate (downstaging/bridging)",
        "local tumour control",
        "local control",
        "tumor reduction",
        "bridging therapy benefit",
        "effectiveness of ablation (multiphase computed tomography with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "progression",
        "tumour spread (TNM system)",
        "prognosis (BCLC staging system)",
        "Barcelona Clinic Liver Cancer (BCLC) staging system",
        "overall condition (ECOG Performance Status)",
        "resectability"
      ],
      "progression_measures": [
        "progression-free state (partitioned survival model)",
        "progressive illness state (partitioned survival model)",
        "disease progression",
        "time to progression of the tumor"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (CTCAE v5.0)",
        "adverse events (Grade ≥ 3)",
        "grade 3 adverse events",
        "grade 4 adverse events",
        "grade 5 adverse events",
        "treatment-emergent adverse events (TEAEs)",
        "adverse reactions",
        "serious adverse events",
        "serious adverse reactions",
        "serious complications",
        "complications",
        "complication incidence",
        "long-term treatment-related complications",
        "side-effects (biopsy)",
        "intraoperative complications",
        "morbidity",
        "bleeding",
        "haemorrhagic events",
        "brain/gastrointestinal bleeding",
        "brain haemorrhage",
        "tumour haemorrhage",
        "secondary cancer",
        "leukaemia",
        "liver disorders",
        "liver failure",
        "hepatic encephalopathy",
        "hepatic encephalopathy (grade > 1 on the New Haven criteria)",
        "hepatic insufficiency",
        "portal vein thrombosis",
        "portal hypertension",
        "ascites",
        "gallbladder abscess",
        "jaundice (EORTC QLQ-HCC18)",
        "jaundice",
        "liver function",
        "liver function (Child-Pugh scale)",
        "nutrition",
        "weight loss",
        "decreased appetite",
        "anorexia",
        "fatigue (EORTC QLQ-HCC18)",
        "fatigue",
        "asthenia",
        "pain (EORTC QLQ-HCC18)",
        "pain",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "body image",
        "distress",
        "physical complaints",
        "psychosocial complaints",
        "fever (EORTC QLQ-HCC18)",
        "fever",
        "dyspnoea",
        "cough",
        "shortness of breath",
        "pleural effusion",
        "nausea",
        "vomiting",
        "constipation",
        "diarrhoea",
        "diarrhoea (grade 3/4)",
        "dry skin",
        "skin rash",
        "rash",
        "skin desquamation",
        "desquamation",
        "erythema",
        "pruritus",
        "dermatitis exfoliative",
        "acne",
        "alopecia",
        "folliculitis",
        "hand-foot-skin reaction",
        "hand-foot skin reaction",
        "hand-foot syndrome",
        "hand feeding reactions (grade 3/4)",
        "hyperkeratosis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "mucosal inflammation",
        "stomatitis",
        "dysphonia",
        "dysgeusia",
        "dyspepsia",
        "dysphagia",
        "gastro oesophageal reflux disease",
        "infections",
        "sepsis",
        "influenza like illness",
        "lymphopenia",
        "leukopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hypophosphataemia",
        "hypertension",
        "hypertension (grade 3/4)",
        "proteinuria",
        "renal failure",
        "myalgia",
        "muscle spasms",
        "arthralgia",
        "back pain",
        "limb pain",
        "joint pain",
        "peripheral sensory neuropathy",
        "tinnitus",
        "flushing",
        "rhinorrhoea",
        "edema",
        "lymphoedema (grade 3/4)",
        "edema",
        "depression",
        "distress",
        "hypothyroidism",
        "hyperthyroidism",
        "diabetes mellitus",
        "infusion reactions",
        "arterial thromboembolic events",
        "cerebral vascular accident",
        "ischaemic stroke",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "cardiovascular arrest",
        "sudden death",
        "death",
        "transient increase in transaminases",
        "increased ALT activity",
        "increased amylase",
        "increased lipase",
        "creatinine increase",
        "QTc prolongation",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "vital signs",
        "electrocardiography",
        "treatment-related deaths",
        "treatment-related mortality",
        "dropout rate for toxicity",
        "adverse reactions leading to discontinuation of treatment",
        "discontinuation of treatment due to adverse events",
        "adverse events leading to discontinuation",
        "need for use of medical resources",
        "days of missed work",
        "length of hospital stay",
        "number needed to harm (NNH)"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions",
        "serious complications"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "discontinuation of treatment due to adverse events",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ-5D visual analogue scale",
        "EQ VAS (Euro QoL visual analogue scale)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep",
        "FHSI-8 questionnaire",
        "overall quality of life (measured with a validated and reliable instrument)",
        "health status (EQ-5D visual analogue scale)",
        "health status (EQ-5D VAS)",
        "global health status (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "quality of life weights"
      ],
      "functional_status": [
        "overall condition (ECOG Performance Status)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "physical complaints",
        "psychosocial complaints"
      ],
      "symptom_measures": [
        "fatigue (EORTC QLQ-HCC18)",
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "distress",
        "body image",
        "nutrition",
        "symptoms",
        "health status",
        "health-related quality of life",
        "health-related quality of life (HRQoL)",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness analysis",
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost per quality-adjusted life year (QALY)",
        "cost-benefit analysis"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights"
      ],
      "resource_utilization": [
        "need for use of medical resources",
        "days of missed work",
        "length of hospital stay",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "plasma pharmacokinetics parameters",
        "pharmacokinetic/pharmacodynamic relationship",
        "pharmacokinetic parameters",
        "diagnosis (multiphasic CT, MRI, CT and MRI Liver Imaging Reporting and Data System (LI-RADS) v2018, contrast-enhanced ultrasound)",
        "pathological examination",
        "immunohistochemistry markers",
        "genetic tests",
        "molecular classification",
        "alpha-fetoprotein (AFP) monitoring",
        "tumour seeding",
        "resectability",
        "burden of disease",
        "success rate (downstaging/bridging)",
        "bridging therapy benefit",
        "early detection of local recurrence",
        "early detection of de novo tumor"
      ],
      "biomarkers": [
        "alpha-fetoprotein (AFP) monitoring"
      ]
    }
  }
}